A phase 2 trial of fludarabine combined with subcutaneous alemtuzumab for the treatment of relapsed/refractory B-cell chronic lymphocytic leukemia

Christopher R. Flowers, Jennifer R. Brown, Hilary Rosenthal, Wendy Stock, Harvey I. Katzen, Jonathon B. Cohen, Rajni Sinha, Shailendra Lakhanpal, Jose F. Leis, Edmund K. Waller, David L. Jaye

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background Alemtuzumab is effective in fludarabine-refractory patients with chronic lymphocytic leukemia. We performed a phase 2 study of alemtuzumab in combination with fludarabine in patients with relapsed disease. Patients and Methods Patients received alemtuzumab and fludarabine daily on days 1 to 5 of a 28-day cycle for up to 6 cycles with the primary objective of determining the rate of complete response. Of 60 enrolled patients, 51 had previously received fludarabine, and 60% had received 3 or more prior therapies. Results Five patients experienced complete response (8.3%) and 12 experienced partial response, yielding an overall response rate of 28.3% for the intention-to-treat population. Among the 41 patients who completed at least 4 cycles of therapy, the complete response rate was 20%. Median progression-free survival was 211 days. Forty-seven percent of patients experienced cytomegalovirus viremia, including 4 patients with symptomatic cytomegalovirus disease. All patients responded to antiviral therapy. Conclusion Despite some evidence of efficacy in this setting, the primary end point for the study was not met. In the era of targeted agents that are well tolerated, the combination of fludarabine and alemtuzumab should be used rarely for a select group of fit patients who are refractory to standard therapies.

Original languageEnglish (US)
Pages (from-to)694-698
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number11
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Keywords

  • Alemtuzumab
  • Chronic lymphocytic leukemia
  • Fludarabine
  • Minimal residual disease
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A phase 2 trial of fludarabine combined with subcutaneous alemtuzumab for the treatment of relapsed/refractory B-cell chronic lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Flowers, C. R., Brown, J. R., Rosenthal, H., Stock, W., Katzen, H. I., Cohen, J. B., Sinha, R., Lakhanpal, S., Leis, J. F., Waller, E. K., & Jaye, D. L. (2015). A phase 2 trial of fludarabine combined with subcutaneous alemtuzumab for the treatment of relapsed/refractory B-cell chronic lymphocytic leukemia. Clinical Lymphoma, Myeloma and Leukemia, 15(11), 694-698. https://doi.org/10.1016/j.clml.2015.07.640